首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >Development and validation of a nomogram for predicting outcome of patients with vulvar cancer.
【24h】

Development and validation of a nomogram for predicting outcome of patients with vulvar cancer.

机译:开发和验证诺模图以预测外阴癌患者的预后。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To construct and validate a nomogram to predict relapse-free survival of patients treated for vulvar cancer. METHODS: Data from 244 patients treated for vulvar cancer at a single institution (Creteil, France) were used as a training set to develop and calibrate a nomogram for predicting relapse-free survival and local relapse-free survival. We used bootstrap resampling for the internal validation and we tested the nomogram on an independent validation set of patients (Torino, Italy) for the external validation. RESULTS: The nomograms were based on a Cox proportional hazards regression model. Covariates for the relapse-free survival model included age, T stage, number of metastatic nodes, bilateral lymph node involvement, omission of the lymphadenectomy, margin status, lymphovascular space invasion, and depth of invasion. The concordance indices were 0.85 and 0.83 in the training set before and after bootstrapping, respectively, and 0.83 in the validation set. The predictions of our nomogram discriminated better than did the International Federation of Gynecology and Obstetrics stage (0.83 compared with 0.78, P = .01). The calibration of our nomogram was good. In the validation set, 2-year and 5-year relapse-free survival were well predicted with less than 5% difference between the predicted and observed survivals for each quartile. A nomogram for predicting local relapse was also developed. CONCLUSION: We have developed nomograms for predicting distant and local relapse of vulvar cancer at 2 and 5 years and validated them both internally and externally. These nomograms will be freely available on the International Society for the Study of Vulvovaginal Disease Web site. LEVEL OF EVIDENCE: III.
机译:目的:构建并验证诺模图以预测外阴癌患者的无复发生存率。方法:将来自单个机构(法国克雷泰尔)的244名外阴癌患者的数据用作训练集,以开发和校准诺模图以预测无复发生存率和局部无复发生存率。我们使用bootstrap重采样进行内部验证,并在独立验证的一组患者(意大利都灵,意大利)上测试了诺模图,以进行外部验证。结果:列线图基于Cox比例风险回归模型。无复发生存模型的协变量包括年龄,T分期,转移淋巴结数目,双侧淋巴结受累,淋巴结清扫术的遗漏,边缘状态,淋巴管空间侵犯和侵犯深度。在自举之前和之后的训练集中,一致性指数分别为0.85和0.83,在验证集中,一致性指数为0.83。与国际妇产科联合会阶段相比,我们对诺模图的预测能更好地进行区分(0.83比0.78,P = 0.01)。我们的列线图的校准很好。在验证集中,可以很好地预测2年和5年无复发生存率,每个四分位数的预测生存率与观察到生存率之间的差异小于5%。还开发了用于预测局部复发的列线图。结论:我们已经开发了诺模图来预测外阴癌在2年和5年的远处和局部复发,并在内部和外部对其进行了验证。这些诺模图将在国际外阴阴道疾病研究网站上免费提供。证据级别:III。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号